Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sensus Healthcare (SRTS) Cash & Equivalents (2016 - 2025)

Sensus Healthcare (SRTS) has 10 years of Cash & Equivalents data on record, last reported at $24.5 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 8.4% year-over-year to $24.5 million; the TTM value through Sep 2025 reached $24.5 million, up 8.4%, while the annual FY2024 figure was $22.1 million, 4.72% down from the prior year.
  • Cash & Equivalents reached $24.5 million in Q3 2025 per SRTS's latest filing, up from $22.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $37.6 million in Q3 2022 and bottomed at $13.7 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $21.9 million, with a median of $20.5 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 140.48% in 2022, then plummeted 45.48% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $14.5 million in 2021, then skyrocketed by 75.77% to $25.5 million in 2022, then decreased by 9.29% to $23.1 million in 2023, then decreased by 4.72% to $22.1 million in 2024, then rose by 10.87% to $24.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $24.5 million in Q3 2025, $22.2 million in Q2 2025, and $19.1 million in Q1 2025.